Yuki sells HRTX 30.52: Finally, Noble Financial restated a buy rating and issued a $41.00 price target (up from $29.00) on shares of Heron Therapeutics in a research report on Thursday, July 23rd.

JMP Securities boosted their target price on shares of Heron Therapeutics from $23.00 to $25.00 and gave the company a market outperform rating in a research report on Friday, May 29th. Leerink Swann reissued an outperform rating and issued a $20.00 price objective on shares of Heron Therapeutics in a report on Friday, May 29th. They set an outperform rating and a $40.00 target price for the company. Cowen and Company started coverage on shares of Heron Therapeutics in a report on Friday, June 26th. In other news, Director Kevin C.


Allison:
We believe that Heron will be able to file the HTX-019 NDA in 2H16, once long-term stability data are generated, since that should take longer than the bioequivalence trial to injectable Emend.

Mandie:
The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.09. On average, analysts forecast that Heron Therapeutics will post ($2.80) EPS for the current fiscal year.

Merrill:
We do not intend to update them except as required by law.

Lena:
These risks and uncertainties include, but are not limited to, those associated with: the acceptance of the Company's resubmission of its New Drug Application (NDA) for SUSTOL, whether the U.S.

Valeria:
Food and Drug Administration (FDA) in July 2015. HTX-019, also being developed for the prevention of CINV, has the potential to become the first polysorbate 80-free, intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist.

Roxy:
Heron's goal is to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use.

Eneida:
Quart, Pharm.D., Chief Executive Officer of Heron.

Dorothy:
In May 2015, the FDA accepted Heron's proposal to use the 505(b)(2) regulatory pathway for HTX-019, Heron's proprietary intravenous formulation of the NK1 receptor antagonist aprepitant for the prevention of CINV.

Gladys:
We caution investors that forward-looking statements reflect our analysis only on their stated date.

Meta:
Heron expects to report results from both of these trials in the second half of 2015. HTX-003, a long-acting formulation of buprenorphine, is being developed for the management of chronic pain and opioid addiction.

Heron Therapeutics Inc. (NASDAQ:HRTX)
//stockhand.net/us/?q=nasdaq%3Ahrtx&id=256533